- Management of direct antiviral agent failures
-
Buti M, Esteban R
- KMID: 2373146
- Clin Mol Hepatol.
- 2016 Dec;22(4):432-438.
- doi: 10.3350/cmh.2016.0107
The current standard of care for patients with chronic hepatitis C virus (HCV) infection is a combination of direct-acting antiviral agents (DAAs). Most HCV patients treated with these drugs achieve... -
- CITED
-
- Close
- SHARE
-
- Close
- Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 2 and 3
-
Jung YK
- KMID: 2373412
- Korean J Gastroenterol.
- 2016 Mar;67(3):132-136.
- doi: 10.4166/kjg.2016.67.3.132
Ever since direct-acting antiviral agents (DAA) have been approved and released into the world, numerous studies on the efficacy, adverse effects and drug-drug interactions of interferon-free DAA combination therapy have... -
- CITED
-
- Close
- SHARE
-
- Close
- Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 1
-
Park SH
- KMID: 2373411
- Korean J Gastroenterol.
- 2016 Mar;67(3):127-131.
- doi: 10.4166/kjg.2016.67.3.127
The introduction of direct-acting antiviral agents (DAAs) has markedly improved the sustained virological response (SVR) rates in patients with chronic hepatitis C. Currently, four classes of DAAs targeting three HCV... -
- CITED
-
- Close
- SHARE
-
- Close
